Besides classical risk factors, interest has also been drawn to other measurable factors that could improve CAD risk assessment for T2DM patients, such as adiponectin and high-sensitivity C-Reactive Protein (hsCRP), among others [12]. This evidence concerns the gene ADIPOQ and type 2 diabetes mellitus.